Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
09:51am, Tuesday, 16'th Jul 2024
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
7 Biotech Stocks to Boost Your Portfolio to Peak Health
02:11pm, Wednesday, 26'th Jun 2024
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
12:15pm, Wednesday, 26'th Jun 2024
Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
06:00am, Wednesday, 26'th Jun 2024
I'm on the hunt for ‘Strong Buy' biotech stocks. According to Finviz.com, there are 680 U.S.-listed biotech stocks.
MENLO PARK, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
10:50am, Friday, 14'th Jun 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
02:34pm, Friday, 07'th Jun 2024
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
02:34pm, Friday, 07'th Jun 2024
The top five biotech stocks today have several commonalities. Among them are strong ratings.
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
12:35pm, Friday, 31'st May 2024
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
12:21pm, Wednesday, 29'th May 2024
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
12:46pm, Thursday, 02'nd May 2024
Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ
Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript
11:42pm, Wednesday, 01'st May 2024
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2024 Earnings Conference Call May 1, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Offi
